Date of this Version
A comprehensive review of prior authorization (PA) requirements for a new class of expensive cholesterol-lowering drugs known as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has found unusually complex and burdensome demands across public and private insurance plans in the United States. These findings raise concerns that current policies may create undue barriers to care even in medically appropriate patients, particularly since requirements were just as stringent for patients with a genetic condition that creates more clear-cut eligibility for PCSK9 inhibitor treatment.
See Original Study
This work is licensed under a Creative Commons Attribution-No Derivative Works 4.0 License.
prior authorization, cholesterol drugs, PCSK9 inhibitors
View On LDI Website
Citation For This Study
Doshi JA, Puckett JT, Parmacek MS, Rader DJ. Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers. Circulation: Cardiovascular Quality and Outcomes, 2018 Jan;11(1):e003939. doi: 10.1161/ CIRCOUTCOMES.117.003939.
Date Posted: 03 April 2018